According to a meta-analysis conducted by Nielsen, D. L based on clinical trials, the incidence of ICI-associated diarrhea was found to be 10.69% for PD-1 inhibitors and 7.97% for PD-L1 inhibitors, while the incidence of colitis was reported to be 1.18% and 0.25%, respectively [4]. The gene discussed is CD274; the disease is colitis.